Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 184, Issue 4, 2001, Pages 429-438

  Van Rompay, Koen K A ^a   McChesney, Michael B ^a   Aguirre, Nancy L ^a   Schmidt, Kimberli A ^a   Bischofberger, Norbert ^b   Marthas, Marta L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; INFECTION PREVENTION; INOCULATION; NEWBORN; NEWBORN INFECTION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VERTICAL TRANSMISSION; VIRUS INFECTION;

ADENINE; ANIMALS; ANTI-HIV AGENTS; ANTIBODIES, VIRAL; DNA, VIRAL; HUMANS; LYMPHOCYTE ACTIVATION; MACACA MULATTA; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0035882425     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/322781     Document Type: Article

References (60)

1. Understanding the timing of HIV transmission from mother to infant
2. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions
3. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomized controlled trial
4. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial
5. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: A randomised trial
6. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial
7. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
8. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
9. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
10. HIV-1 drug resistance in newly infected individuals
11. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia
12. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA
13. Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines
14. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1-infected adults
15. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques
16. Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl)adenine (PMPA)
17. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA
18. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection
19. Metabolism and pharmacokinetics of a novel oral prodrug of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs
20. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection
21. Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection
22. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS
23. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: Oral 3-azido-3-deoxythymidine prevents SIV infection
24. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251
25. 9-[2-(phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques
26. Performance characteristics of a highly sensitive quantitative assay for SIV RNA using branched DNA technology
27. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay
28. Occult systemic infection and persistent simian immunodeficiency virus (SIV)-specific proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV
29. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
30. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques
31. Early short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques
32. 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA
33. Safety, pharmacokinetics and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults
34. Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation
35. Reactivation of HIV type 1 in chronically infected chimpanzees following xenostimulation with human cells or with pulses of corticosteroid
36. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): Safety and efficacy studies
37. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2)
38. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl)adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment
39. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre-and postexposure administration of BEA-005
40. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera
41. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
42. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis
43. Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus
44. Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase
45. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors
46. Cellular immunity and target cell susceptibility in persons with repeated HIV-1 exposure
47. Immune responses in HIV-exposed seronegatives: Have they repelled the virus?
48. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons
49. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects
50. Human immunodeficiency virus-indeterminate Western blot and abortive infection
51. Indeterminate human immunodeficiency virus type 1 Western blot may indicate an abortive infection in some low-risk blood donors
52. Antigen detection, virus culture, polymerase chain reaction, and in vitro antibody production in the diagnosis of vertically transmitted HIV-1 infection
53. Clearance of HIV infection in a perinatally infected infant
54. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1
55. Activation of virus replication after vaccination of HIV-1-infected individuals
56. Animal studies of prophylaxis
57. Simian immunodeficiency virus